Clinical Trial Update: Tezepelumab Efficacy and Safety in Reducing Oral Corticosteroid Use in Adults With Oral Corticosteroid Dependent Asthma [Phase 3]

View source ↗

Summary

Phase 3 trial evaluating tezepelumab to reduce oral corticosteroid use in adults with oral corticosteroid-dependent asthma; the study is terminated.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Asthma

Drugs mentioned

• Tezspire (tezepelumab)

Snippet

Sponsor: AstraZeneca | Conditions: Asthma | Phase 3 | Status: TERMINATED